We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

History

AC Immune’s history is built on excellence in science and strong leadership in the field of diseases involving misfolded proteins. Since 2003, we have been dedicated to improving the lives of patients suffering from Alzheimer’s and other neurodegenerative diseases. All programs in our pipeline originate from our two proprietary technology platforms.

2020

Second Milestone Payment and New Milestone in Lilly small molecule Morphomer™ Tau aggregation inhibitor program

2019

First Milestone Payment from Lilly in small molecule Morphomer™ Tau aggregation inhibitor program

2019

Milestone payment from Life Molecular Imaging in connection with the initiation of a Phase 2 study of the Tau-PET tracer PI-2620

2018

Eli Lilly- License and Collaboration Agreement focuses on small molecule Morphomer™ Tau aggregation inhibitors

2018

Genentech milestone payment 3 (anti-Tau antibody semorinemab)

2017

Essex Bio-Technology research collaboration for neurodegenerative diseases and neuroinflammation

2016

Initial Public Offering (IPO) on NASDAQ

2016

Genentech milestone payment 2 (anti-Tau antibody semorinemab)

2016

Biogen research and development collaboration for diagnostics in neurodegenerative diseases

2015

Nestlé Institute of Health Science research collaboration for Tau diagnostic assay

2015

Genentech milestone payment 3 (anti-Abeta antibody crenezumab)

2015

Genentech milestone payment 1 (anti-Tau antibody semorinemab)

2015

Janssen Pharmaceuticals licensing agreement for anti-Tau therapeutic vaccine ($509 million)

2014

Piramal Imaging (now Life Molecular Imaging) licensing agreement for anti-Tau diagnostic (significant value)

2012

Genentech licensing agreements for anti-Tau antibody semorinemab ($418 million)

2011

Genentech milestone payment 2 (anti-Abeta antibody crenezumab)

2009

E&Y Entrepreneur of the Year
WEF Technology Pioneer

2009

Bayer Schering collaboration for brain imaging taken over by Piramal Imaging (now Life Molecular Imaging)

2008

Genentech milestone payment 1 (anti-Abeta antibody crenezumab)

2006

Genentech licensing agreements for anti-Abeta antibody crenezumab ($300 million)

2003

Foundation of AC Immune

2020

Second Milestone Payment and New Milestone in Lilly small molecule Morphomer™ Tau aggregation inhibitor program

2019

First Milestone Payment from Lilly in small molecule Morphomer™ Tau aggregation inhibitor program

2019

Milestone payment from Life Molecular Imaging in connection with the initiation of a Phase 2 study of the Tau-PET tracer PI-2620

2018

Eli Lilly- License and Collaboration Agreement focuses on small molecule Morphomer™ Tau aggregation inhibitors

2018

Genentech milestone payment 3 (anti-Tau antibody semorinemab)

2017

Essex Bio-Technology research collaboration for neurodegenerative diseases and neuroinflammation

2016

Initial Public Offering (IPO) on NASDAQ

2016

Genentech milestone payment 2 (anti-Tau antibody semorinemab)

2016

Biogen research and development collaboration for diagnostics in neurodegenerative diseases

2015

Nestlé Institute of Health Science research collaboration for Tau diagnostic assay

2015

Genentech milestone payment 3 (anti-Abeta antibody crenezumab)

2015

Genentech milestone payment 1 (anti-Tau antibody semorinemab)

2015

Janssen Pharmaceuticals licensing agreement for anti-Tau therapeutic vaccine ($509 million)

2014

Piramal Imaging (now Life Molecular Imaging) licensing agreement for anti-Tau diagnostic (significant value)

2012

Genentech licensing agreements for anti-Tau antibody semorinemab ($418 million)

2011

Genentech milestone payment 2 (anti-Abeta antibody crenezumab)

2009

E&Y Entrepreneur of the Year
WEF Technology Pioneer

2009

Bayer Schering collaboration for brain imaging taken over by Piramal Imaging (now Life Molecular Imaging)

2008

Genentech milestone payment 1 (anti-Abeta antibody crenezumab)

2006

Genentech licensing agreements for anti-Abeta antibody crenezumab ($300 million)

2003

Foundation of AC Immune

Partnerships
Financing / Milestone Payments
Other Milestones